E
Edward T. Creagan
Researcher at Mayo Clinic
Publications - 175
Citations - 6643
Edward T. Creagan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Chemotherapy & Regimen. The author has an hindex of 39, co-authored 175 publications receiving 6352 citations.
Papers
More filters
Journal ArticleDOI
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.
Charles G. Moertel,Thomas R. Fleming,Edward T. Creagan,Joseph Rubin,Michael J. O'Connell,Matthew M. Ames +5 more
TL;DR: It can be concluded that high-dose vitamin C therapy is not effective against advanced malignant disease regardless of whether the patient has had any prior chemotherapy.
Journal ArticleDOI
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.
Edward T. Creagan,Charles G. Moertel,Judith R. O'Fallon,Allan J. Schutt,Michael J. O'Connell,Joseph Rubin,Stephen Frytak +6 more
TL;DR: The two groups showed no appreciable difference in changes in symptoms, performance status, appetite or weight, and were unable to show a therapeutic benefit of high-dose vitamin C treatment.
Journal ArticleDOI
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
Svetomir N. Markovic,Lori A. Erickson,Ravi D. Rao,Robert R. McWilliams,Lisa A. Kottschade,Edward T. Creagan,Roger H. Weenig,Jennifer L. Hand,Mark R. Pittelkow,Barbara A. Pockaj,Aditya Bardia,Celine M. Vachon,Steven E. Schild,Susan D. Laman,William J. Maples,Jose S. Pulido,J. Douglas Cameron +16 more
TL;DR: Management of systemic melanoma is a challenge because of a paucity of active treatment modalities and several clinically relevant pathologic subtypes have been identified and need to be recognized.
Journal ArticleDOI
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.
James N. Ingle,David L. Ahmann,Green Sj,John H. Edmonson,Harry F. Bisel,Larry K. Kvols,Nichols Wc,Edward T. Creagan,Richard G. Hahn,Joseph Rubin,Stephen Frytak +10 more
TL;DR: Since there was no statistically significant difference in efficacy and since tamoxifen was less toxic, tamoxIFen appears to be the preferred agent.
Journal ArticleDOI
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.
Edward T. Creagan,Robert J. Dalton,D. L. Ahmann,Sin-Ho Jung,Roscoe F. Morton,R. M. Langdon,John W. Kugler,L. J. Rodrigue +7 more
TL;DR: Findings indicate trends that suggest a possible benefit for selected patients with high-risk malignant melanoma, which will require further study in a larger patient population for confirmation.